Dr Mark Gurnell

Mark Gurnell

University position

Senior Lecturer

Dr Mark Gurnell is pleased to consider applications from prospective PhD students.

Departments

Department of Medicine

Institutes

Institute of Metabolic Science

Email

mg299@medschl.cam.ac.uk

Home page

http://www.mrl.ims.cam.ac.uk

Research Themes

Clinical and Veterinary Neuroscience

Cognitive and Behavioural Neuroscience

Interests

Current programmes of research:

1. endocrine basis of financial decision-making

2. genetic and acquired disorders of the hypothalamic-pituitary-thyroid axis

3. novel approaches to sparing hypothalamic-pituitary function in patients with sellar/parasellar tumours

4. functional imaging in endocrine neoplasia

5. optimizing outcomes in acromegaly.

Functional imaging in human pituitary disease
Click image to view full-size

Research Focus

Keywords

pituitary

thyroid

adrenal

imaging

finance

Clinical conditions

Genetic disorders

Hormonal disorders

Equipment

Computerised tomography

Cross-sectional and cohort studies

Immunohistochemistry

Magnetic resonance imaging (MRI)

Neuropsychological testing

Positron Emission Tomography (PET)

Randomised control trials

Collaborators

Cambridge

Neil Burnet

Krishna Chatterjee

John Coates

Paul Fletcher

John Pickard

Nadia schoenmakers

Associated News Items


    Publications

    2014

    Kandasamy N, Hardy B, Page L, Schaffner M, Graggaber J, Powlson AS, Fletcher PC, Gurnell M, Coates J (2014), “Cortisol shifts financial risk preferences.” Proc Natl Acad Sci U S A Details

    2013

    Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O'Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013), “A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.” J Clin Endocrinol Metab 98(3):1040-50 Details

    Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ, UK Acromegaly Register Study Group (UKAR-3) (2013), “Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.” Clin Endocrinol (Oxf) 79(5):689-99 Details

    Justin C, Annamalai AK, Pricilla G, Muralidharan K, Srinivasan KG, Gurnell M (2013), “More than just morning sickness.” QJM 106(12):1123-5 Details

    Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, Fenwick S, Webb A, Wark G, Pleasance S, Gurnell M (2013), “A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly.” Clin Endocrinol (Oxf) 78(3):424-30 Details

    Koulouri O, Gurnell M (2013), “How to interpret thyroid function tests.” Clin Med 13(3):282-6 Details

    Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M (2013), “Pitfalls in the measurement and interpretation of thyroid function tests.” Best Pract Res Clin Endocrinol Metab 27(6):745-62 Details

    Moran C, Schoenmakers N, Agostini M, Schoenmakers E, Offiah A, Kydd A, Kahaly G, Mohr-Kahaly S, Rajanayagam O, Lyons G, Wareham N, Halsall D, Dattani M, Hughes S, Gurnell M, Park SM, Chatterjee K (2013), “An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α.” J Clin Endocrinol Metab 98(11):4254-61 Details

    Schoenmakers N, Moran C, Peeters RP, Visser T, Gurnell M, Chatterjee K (2013), “Resistance to thyroid hormone mediated by defective thyroid hormone receptor alpha.” Biochim Biophys Acta 1830(7):4004-8 Details

    2012

    Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M (2012), “Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.” Pituitary 15(3):276-87 Details

    Annamalai AK, Powlson AS, Kandasamy N, Lodge K, Graggaber J, Halsall DJ, Antoun NM, Cheow HK, Buttery PC, George E, Griffiths M, Price SJ, Pickard JD, Sivasothy P, Gurnell M (2012), “Hypopituitarism, pulmonary infiltration and a spontaneously resolving occipital mass.” QJM Details

    Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam O, Keogh JM, Henning E, Reinemund J, Gevers E, Sarri M, Downes K, Offiah A, Albanese A, Halsall D, Schwabe JW, Bain M, Lindley K, Muntoni F, Vargha-Khadem F, Dattani M, Farooqi IS, Gurnell M, Chatterjee K (2012), “A mutation in the thyroid hormone receptor alpha gene.” N Engl J Med 366(3):243-9 Details

    Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EA, Aigbirhio F, Gurnell M, Brown MJ (2012), “Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas.” J Clin Endocrinol Metab 97(1):100-9 Details

    Halsall DJ, Gurnell M (2012), “Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.” Ann Clin Biochem 49(Pt 2):204; author reply 204-5 Details

    2011

    Annamalai AK, Gayton EL, Webb A, Halsall DJ, Rice C, Ibram F, Chaudhry AN, Simpson HL, Berman L, Gurnell M (2011), “Increased prevalence of gallbladder polyps in acromegaly.” J Clin Endocrinol Metab 96(7):E1120-5 Details

    Gurnell M, Halsall DJ, Chatterjee VK (2011), “What should be done when thyroid function tests do not make sense?” Clin Endocrinol (Oxf) 74(6):673-8 Details

    Kandasamy N, Annamalai AK, Antoun N, Gurnell M (2011), “Hypotension, polyuria and a cardiac arrest.” QJM 104(5):437-8 Details

    2010

    Castanet M, Mallya U, Agostini M, Schoenmakers E, Mitchell C, Demuth S, Raymond FL, Schwabe J, Gurnell M, Chatterjee VK (2010), “Maternal isodisomy for chromosome 9 causing homozygosity for a novel FOXE1 mutation in syndromic congenital hypothyroidism.” J Clin Endocrinol Metab 95(8):4031-6 Details

    Coates JM, Gurnell M, Sarnyai Z (2010), “From molecule to market: steroid hormones and financial risk-taking.” Philos Trans R Soc Lond B Biol Sci 365(1538):331-43 Details

    Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, Rajanayagam O, Padidela R, Ceron-Gutierrez L, Doffinger R, Prevosto C, Luan J, Montano S, Lu J, Castanet M, Clemons N, Groeneveld M, Castets P, Karbaschi M, Aitken S, Dixon A, Williams J, Campi I, Blount M, Burton H, Muntoni F, O'Donovan D, Dean A, Warren A, Brierley C, Baguley D, Guicheney P, Fitzgerald R, Coles A, Gaston H, Todd P, Holmgren A, Khanna KK, Cooke M, Semple R, Halsall D, Wareham N, Schwabe J, Grasso L, Beck-Peccoz P, Ogunko A, Dattani M, Gurnell M, Chatterjee K (2010), “Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans.” J Clin Invest 120(12):4220-35 Details

    2009

    Coates JM, Gurnell M, Rustichini A (2009), “Second-to-fourth digit ratio predicts success among high-frequency financial traders.” Proc Natl Acad Sci U S A 106(2):623-8 Details

    Jeninga EH, Gurnell M, Kalkhoven E (2009), “Functional implications of genetic variation in human PPARgamma.” Trends Endocrinol Metab 20(8):380-7 Details

    Mankia SK, Weerakkody RA, Wijesuriya S, Kandasamy N, Finucane F, Guilfoyle M, Antoun N, Pickard J, Gurnell M (2009), “Spontaneous cerebrospinal fluid rhinorrhoea as the presenting feature of an invasive macroprolactinoma.” BMJ Case Rep 2009 Details

    2007

    Gurnell M (2007), “'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies.” PPAR Res 2007:83593 Details

    Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ (2007), “The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.” Eur J Endocrinol 157(4):533-7 Details

    Szatmari I, Töröcsik D, Agostini M, Nagy T, Gurnell M, Barta E, Chatterjee K, Nagy L (2007), “PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism.” Blood 110(9):3271-80 Details

    2006

    Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais D, Schwabe J, Barroso I, Trembath R, Wareham N, Nagy L, Gurnell M, O'Rahilly S, Chatterjee K (2006), “Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.” Cell Metab 4(4):303-11 Details

    Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ, O'Rahilly S (2006), “Elevated plasma adiponectin in humans with genetically defective insulin receptors.” J Clin Endocrinol Metab 91(8):3219-23 Details

    2005

    Gurnell M (2005), “Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies.” Best Pract Res Clin Endocrinol Metab 19(4):501-23 Details

    Semple RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK, O'Rahilly S (2005), “A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.” Endocrinology 146(4):1871-82 Details

    2004

    Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK (2004), “Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.” Endocrinology 145(4):1527-38 Details

    Gurnell M, Chatterjee VK (2004), “Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors.” Essays Biochem 40:169-89 Details

    2003

    Gurnell M (2003), “PPARgamma and metabolism: insights from the study of human genetic variants.” Clin Endocrinol (Oxf) 59(3):267-77 Details

    Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S (2003), “The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.” J Clin Endocrinol Metab 88(6):2412-21 Details

    Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S (2003), “Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.” Diabetes 52(4):910-7 Details

    2002

    Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ (2002), “Digenic inheritance of severe insulin resistance in a human pedigree.” Nat Genet 31(4):379-84 Details

    2000

    Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK (2000), “A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.” J Biol Chem 275(8):5754-9 Details

    1999

    Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S (1999), “Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.” Nature 402(6764):880-3 Details

    Gurnell M, Rajanayagam O, Agostini M, Clifton-Bligh RJ, Wang T, Zelissen PM, van der Horst F, van de Wiel A, Macchia E, Pinchera A, Schwabe JW, Chatterjee VK (1999), “Three novel mutations at serine 314 in the thyroid hormone beta receptor differentially impair ligand binding in the syndrome of resistance to thyroid hormone.” Endocrinology 140(12):5901-6 Details

    1998

    Collingwood TN, Wagner R, Matthews CH, Clifton-Bligh RJ, Gurnell M, Rajanayagam O, Agostini M, Fletterick RJ, Beck-Peccoz P, Reinhardt W, Binder G, Ranke MB, Hermus A, Hesch RD, Lazarus J, Newrick P, Parfitt V, Raggatt P, de Zegher F, Chatterjee VK (1998), “A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.” EMBO J 17(16):4760-70 Details

    Gurnell M, Rajanayagam O, Barbar I, Jones MK, Chatterjee VK (1998), “Reversible pituitary enlargement in the syndrome of resistance to thyroid hormone.” Thyroid 8(8):679-82 Details

    1997

    Cunningham R, Gurnell M, Bayston R, Cockayne A, Shelton A (1997), “Teicoplanin resistance in Staphylococcus haemolyticus, developing during treatment.” J Antimicrob Chemother 39(3):438-9 Details

    Macchia E, Gurnell M, Agostini M, Giorgilli G, Marcocci C, Valenti TM, Martino E, Chatterjee KK, Pinchera A (1997), “Identification and characterization of a novel de novo mutation (L346V) in the thyroid hormone receptor beta gene in a family with generalized thyroid hormone resistance.” Eur J Endocrinol 137(4):370-6 Details

    1990

    Nistri A, Fisher ND, Gurnell M (1990), “Block by the neuropeptide TRH of an apparently novel K+ conductance of rat motoneurones.” Neurosci Lett 120(1):25-30 Details